Abstract:DNA methylation, an epigenetic regulatory mechanism dictating gene transcription, plays a critical role in the occurrence and development of cancer. However, the molecular underpinnings of LINC00987 methylation in the regulation of lung adenocarcinoma (LUAD) remain elusive. This study investigated LINC00987 expression in LUAD patients through analysis of The Cancer Genome Atlas data sets. Quantitative real‐time polymerase chain reaction (RT‐qPCR) and fluorescence in situ hybridization assays were used to assess LINC00987 expression in LUAD. The bisulfite genomic sequence PCR (BSP) assay was used to determine the methylation levels of the LINC00987 promoter. The interaction between LINC00987 and SND1 was elucidated via immunoprecipitation and RNA pull‐down assays. The functional significance of LINC00987 and SND1 in Calu‐3 and NCI‐H1688 cells was evaluated in vitro through CCK‐8, EdU, Transwell, flow cytometry, and vasculogenic mimicry (VM) tube formation assays. LINC00987 expression decreased in LUAD concomitant with hypermethylation of the promoter region, while hypomethylation of the LINC00987 promoter in LUAD tissues correlated with tumor progression. Treatment with 5‐Aza‐CdR augmented LINC00987 expression and inhibited tumor growth. Mechanistically, LINC00987 overexpression impeded LUAD progression and VM through direct binding with SND1, thereby facilitating its phosphorylation and subsequent degradation. Additionally, overexpression of SND1 counteracted the adverse effects of LINC00987 downregulation on cell proliferation, apoptosis, cell migration, invasion, and VM in LUAD in vitro. In conclusion, this pioneering study focuses on the expression and function of LINC00987 and reveals that hypermethylation of the LINC00987 gene may contribute to LUAD progression. LINC00987 has emerged as a potential tumor suppressor gene in tumorigenesis through its binding with SND1 to facilitate its phosphorylation and subsequent degradation.

The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy

Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9

RETRACTED ARTICLE: MicroRNA-495 mimics delivery inhibits lung tumor progression

Preparation, characterisation, and in vitro cancer-suppression function of RNA nanoparticles carrying miR-301b-3p Inhibitor

miR-140-3p enhances cisplatin sensitivity and attenuates stem cell-like properties through repressing Wnt/β-catenin signaling in lung adenocarcinoma cells

The Mechanism of DNA Methylation and miRNA in Breast Cancer

Mir-550A-5p Functions As a Tumor Promoter by Targeting LIMD1 in Lung Adenocarcinoma

Evaluation of miR-155 silencing using a molecular beacon in human lung adenocarcinoma cell line

DNA Methylation Mediated Silencing of Microrna-145 is a Potential Prognostic Marker in Patients with Lung Adenocarcinoma

MiR-937-3p Promotes Metastasis and Angiogenesis and is Activated by MYC in Lung Adenocarcinoma

Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer.

Epigenetic Alterations of DNA Methylation and miRNA Contribution to Lung Adenocarcinoma

Nanostructured lipid carriers for MicroRNA delivery in tumor gene therapy

Hypomethylation‐associated LINC00987 downregulation induced lung adenocarcinoma progression by inhibiting the phosphorylation‐mediated degradation of SND1

MiR-629-5p Promotes the Invasion of Lung Adenocarcinoma Via Increasing Both Tumor Cell Invasion and Endothelial Cell Permeability

Reversing the negative effect of adenosine A1 receptor-targeted immunometabolism modulation on melanoma by a co-delivery nanomedicine for self-activation of anti-PD-L1 DNAzyme

miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways

miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A

Downregulation of miRNA-126-3p is associated with progression of and poor prognosis for lung squamous cell carcinoma

Biomembrane-derived nanoplexes for SiRNAs-pioneer innovation in delivery to lung adenocarcinoma